title: Selective inhibition of systemic anti-OVA IgE production in response to oral pre-treatment with OVA-liposome conjugates.
abstract: BACKGROUND
  We have previously reported that intraperitoneal injection with OVA-liposome conjugates induces OVA-specific and IgE-selective unresponsiveness in mice.
  
  
  METHODS
  In the present study, the effects of oral pre-treatment with OVA-liposome conjugates or with plain OVA solution on anti-OVA IgG antibody production were investigated in mice after subsequent immunization with alum-adsorbed OVA. Control mice received only the immunization.
  
  
  RESULTS
  The levels of serum anti-OVA IgG antibody in mice receiving oral administration of OVA-liposome were comparable to those in the control mice. However, in mice receiving oral administration of the same dose of plain OVA, levels of serum anti-OVA IgG antibody were significantly lower than those in control mice. Surprisingly, anti-OVA IgE antibody production was completely inhibited in mice receiving oral administration of OVA-liposome conjugates. Splenic CD4(+) T cells of mice receiving oral administration of OVA-liposome and those of control mice produced comparable levels of cytokines, while those of mice receiving oral administration of plain OVA solution produced significantly lower levels of cytokines than those in the other two groups.
  
  
  CONCLUSIONS
  Orally administered OVA-liposome did not affect anti-OVA IgG production but did inhibit anti-OVA IgE antibody production, while orally administered OVA solution inhibited production of both IgG and IgE antibodies. These results suggest that antigen-liposome conjugates can possibly be orally administered in order to control antigen-specific IgE antibody production, without affecting IgG antibody production.
authors.affiliation: Department of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases, Musashimurayama, Tokyo, Japan.
authors.forename: Seishiro
authors.initials: S
authors.lastname: Naito
authors.forename: Maiko
authors.initials: M
authors.lastname: Taneichi
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Kato
authors.forename: Yuriko
authors.initials: Y
authors.lastname: Tanaka
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Ami
authors.forename: Yuriko
authors.initials: Y
authors.lastname: Suzaki
authors.forename: Masahito
authors.initials: M
authors.lastname: Mori
authors.forename: Yoshio
authors.initials: Y
authors.lastname: Nakano
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Yamamura
authors.forename: Kazunori
authors.initials: K
authors.lastname: Morokuma
authors.forename: Kunio
authors.initials: K
authors.lastname: Ohkuma
authors.forename: Hidekazu
authors.initials: H
authors.lastname: Miyake
authors.forename: Mamoru
authors.initials: M
authors.lastname: Kiniwa
authors.forename: Katsutoshi
authors.initials: K
authors.lastname: Komuro
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Uchida
mesh_terms: D000284:Administration, Oral; D000485:Allergens / Q000008:administration & dosage; D000534:Alum Compounds / Q000008:administration & dosage; D000818:Animals; D000918:Antibody Specificity; D016207:Cytokines / Q000096:biosynthesis; D005260:Female; D007115:Immunization Schedule; D007073:Immunoglobulin E / Q000096:biosynthesis* / Q000097:blood; D007074:Immunoglobulin G / Q000096:biosynthesis / Q000097:blood; D008081:Liposomes; D051379:Mice; D008807:Mice, Inbred BALB C; D010047:Ovalbumin / Q000008:administration & dosage* / Q000276:immunology*
chemical_list: D000485:Allergens; D000534:Alum Compounds; D016207:Cytokines; D007074:Immunoglobulin G; D008081:Liposomes; C041524:aluminum sulfate; D007073:Immunoglobulin E; D010047:Ovalbumin